William Aird/X
Jul 7, 2025, 11:42
What Drives Essential Thrombocythemia? Dr. William Aird on the Pathophysiology of Platelet Overproduction
Dr. William Aird, Professor of Medicine at Harvard Medical School, has posted on X:
“Essential Thrombocythemia (ET) Pathophysiology
ET is driven by one of 3 mutations:
- JAK2 V617F → cytokine-independent signaling
- CALR → abnormal MPL activation
- MPL → constitutive TPO receptor signaling
All lead to unchecked megakaryocyte proliferation and ↑ platelets.”
Curious about what drives Essential Thrombocythemia? Here’s a quick look at the mutations involved.
Explore more on Hemostasis Today.
-
Feb 25, 2026, 16:47Alan Nurden: Platelet Defects Explain Bleeding in EHDS Patients
-
Feb 25, 2026, 16:40Mohammed Almohammadi: Uniting Leaders in Laboratory Hematology at the 1st Saudi ISLH Joint Conference
-
Feb 25, 2026, 16:37Salihu Asimawu: Inflammation Is Not a Disease – Hats Off to the Heroes Inside Us
-
Feb 25, 2026, 16:34Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
-
Feb 25, 2026, 16:25Tagreed Alkaltham: The Blood Banker Personality
-
Feb 25, 2026, 16:17Sanjay Ahuja: Insightful Talk on 100 Years of VWD by Jorge Di Paola
-
Feb 25, 2026, 15:20Michael Shapiro։ Creating Real Pathways for Trainees in Preventive Cardiology
-
Feb 25, 2026, 15:15Ajay Kumar: Plasma Component Quality Control Standards
-
Feb 25, 2026, 15:09Wolfgang Miesbach: Efficacy, Safety and Thrombosis Signals in Haemophilia A/B with Inhibitors